Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 81,09 € (-10,15 %). Medianen er 81,09 € (-10,15 %).
| Køb |
Â
10 |
| Behold |
Â
3 |
| Sælg |
Â
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
U.S. Physical Therapy expands hospital alliances with NYU Langone to boost visits and reimbursement
U.S. Physical Therapy is pursuing growth through clinic openings, acquisitions and hospital alliances, highlighted by a 10-year NYU Langone partnership that added 60 New York locations and yields flat per-visit payments with higher, more predictable reimbursement. The company opens about 25–30 clinics organically and acquires 30–70 annually using a local-partnership model that preserves clinician ownership and brands. Its injury-prevention unit has grown to roughly $120 million in revenue and more than $20 million in EBITDA, delivering margins about twice those of the physical therapy segment. Management reports about $220 million in debt, expects EBITDA above $100 million for the year, and has capital available for further expansion and share repurchases. » Mere på finance.yahoo.com
U.S. Physical Therapy relies on partnerships and Briotix to offset Medicare pressure
U.S. Physical Therapy pursues a growth strategy based on a partnership model, hospital alliances (including an exclusive deal with NYU Langone) and expansion of its Briotix division to compensate for lower Medicare reimbursements and competition in the outpatient market. The NYU partnership is expected to bring about 700,000 additional treatments per year long term; Briotix generates roughly $120 million in revenue with substantially higher margins than the physical therapy business. Management views debt of about $220 million and expected EBITDA above $100 million as a manageable framework; it anticipates recoveries in Medicare reimbursement from 2024/2025 and stronger increases from 2028. » Mere på de.investing.com
Nchacha Etta to become CFO of U.S. Physical Therapy
U.S. Physical Therapy appoints Nchacha Etta effective September 1, 2026, as executive vice president and chief financial officer. Etta previously served as CFO at Omnicell and held financial leadership roles at Essilor of America, Johnson & Johnson Vision and Coca‑Cola; he also sits on the board of directors of KBR. Jason Curtis will remain senior vice president for finance and accounting and will return to that role after serving as interim CFO. U.S. Physical Therapy operates 796 outpatient physical therapy clinics in 45 U.S. states. » Mere på de.investing.com
U.S. Physical Therapy expands into new U.S. state through acquisition
U.S. Physical Therapy has acquired a physiotherapy group with 12 clinics, taking a 67% stake in the company while the previous owners retain 33%. The acquired group delivers about 112,000 treatments per year and generates annual revenue of USD 12 million. With the purchase, U.S. Physical Therapy increases its presence from 44 to 45 states and now operates 795 outpatient clinics; trailing twelve‑month revenue is USD 788 million. » Mere på de.investing.com
U.S. Physical Therapy misses Q1 2026 forecasts, stock falls
U.S. Physical Therapy reported a GAAP loss per share of $0.12 for Q1 2026, missing the expected $0.54 by a wide margin; revenue was $198 million (expectation $200.26 million), a year‑over‑year increase of 7.9%. Weather‑related cancellations of roughly 31,000 patient appointments are estimated to have reduced revenue by about $3.3 million. The stock fell roughly 2% in after‑hours trading; management plans to push efficiency measures, virtualize reception areas, implement AI‑assisted documentation, and expand self‑pay offerings. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 196,49 mio. | 40,58 % |
| Bruttofortjeneste | 37,99Â mio. | 20,91Â % |
| Nettoresultat | 9,75Â mio. | 57,99Â % |
| EBITDA | 27,71Â mio. | 4,52Â % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,33 mia. € |
Antal aktier | 14,93Â mio. |
Højeste/laveste i 52 uger | 91,16 € - 52,43 € |
Udbytteafkast | 1,74Â % |
Udbytte TTM | 1,57 € |
Næste udbytte | 0,41 € |
Beta | 1,13 |
P/E (PE Ratio) | -73,51 |
PEG (PEG Ratio) | 0,47 |
K/I (PB Ratio) | 3,45 |
P/S (PS Ratio) | 1,77 |
Virksomhedsprofil
U.S. Physical Therapy, Inc. driver gennem sine datterselskaber ambulante fysioterapiklinikker, der leverer præ- og postoperativ behandling og pleje ved ortopædisk relaterede lidelser, sportsskader, forebyggende pleje, rehabilitering af arbejdsskadede og neurologisk relaterede skader. Virksomheden opererer gennem to segmenter, Physical Therapy Operations og Industrial Injury Prevention Services. Selskabet tilbyder industrielle skadesforebyggelsesydelser, herunder skadesforebyggelse og rehabilitering på arbejdspladsen, optimering af præstationer, ansættelsestests efter jobtilbud, funktionsevnevurderinger og ergonomiske vurderinger gennem fysioterapeuter og specialiserede certificerede athletic trainers for Fortune 500-virksomheder og andre kunder, herunder forsikringsselskaber og deres entreprenører. Pr. 31. december 2021 drev den 591 klinikker i 39 stater og forvaltede 35 fysioterapeutiske praksisfaciliteter. Virksomheden blev grundlagt i 1990 og har hovedkontor i Houston, Texas.
| Navn | U.S. Physical Therapy |
| CEO | Christopher J. Reading |
| Hjemsted | Houston,
tx USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudbydere og -tjenester |
| Børsnotering | 29.05.1992 |
| Medarbejdere | 6.374 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | USPH |
Frankfurt | UPH.F |
DĂĽsseldorf | UPH.DU |